Patent Application
20100184052
The present invention relates to the field of cancer prognosis and diagnosis. More particular, the invention relates to a method for typing an RNA sample of an individual suffering from non-small cell lung cancer. The invention furthermore relates to a set of genes or probes for use in typing an RNA sample of said individual.
Lung cancer accounts for about 15% of all diagnosed cancers in human and causes the most cancer-related deaths in both men and women (source: Cancer facts and Figures 2007, American Cancer Society). The three main types of primary lung cancers are mesothelioma, small cell lung cancer, and non-small cell lung cancer. Mesothelioma is a rare type of cancer which affects the covering of the lung (the pleura). It is often caused by exposure to asbestos. Small cell lung cancer (SCLC), also called oat cell lung cancer, is characterized by the presence of small cells that are almost entirely composed of a nucleus. SCLC frequently occurs in (ex)smokers and is quite rare for people that never smoked. SCLC tends to spread early in development of the tumor and is often treated with chemotherapy rather than surgery. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and is diagnosed in about 85% of all lung cancer patients. NSCLC represents a diverse group of cancers with the main groups being squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Other, minor groups comprise pleomorphic carcinoma, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma.
Adenocarcinoma is the most common subtype of NSCLC, accounting for 50% to 60% of NSCLC. It is a form which starts near the gas-exchanging surface of the lung. Most cases of the adenocarcinoma are associated with smoking.
However, among non-smokers and in particular female non-smokers, adenocarcinoma is the most common form of lung cancer. A subtype of adenocarcinoma, the bronchioalveolar carcinoma, is more common in female non-smokers and may have different responses to treatment. Squamous cell carcinoma, accounting for 20% to 25% of NSCLC, also starts in the larger breathing tubes but grows slower meaning that the size of these tumours varies on diagnosis. Large-cell carcinoma accounts for about 10% to 15% of NSCLC. It can start in any part of the lung. It tends to grow and spread quickly.
Known risk factors for developing NSCLC are smoking, actively or passively, exposure to air pollution, and exposure to radiation. When smoking is combined with other risk factors, the risk of developing lung cancer is increased.
There are multiple tests and procedures to detect, diagnose, and stage non-small cell lung cancer. Performing a chest X-ray is often the first step if a patient reports symptoms that may be suggestive of lung cancer. This may reveal an obvious mass, widening of the mediastinum (suggestive of spread to lymph nodes there), atelectasis (collapse), consolidation (infection) and pleural effusion. If there are no X-ray findings but the suspicion is high (e.g. a heavy smoker with blood-stained sputum), bronchoscopy and/or a CT scan may provide the necessary information. In any case, bronchoscopy or CT-guided biopsy is nearly always performed to identify the tumor type and to determine the stage.
If investigations have confirmed lung cancer, scan results; and often positron emission tomography (PET) are used to determine whether the disease is localized and amenable to surgery or whether it has spread to the point it cannot be cured surgically.
Prognosis and treatment options depend on the stage of the cancer, the type of cancer, and the patient's general health. Early stage cancer is primarily treated by surgery, which is aimed at removing all cancer cells. Surgery can lead to the removal of all or part of a lung, depending on the location and size of the cancer.
Alternative treatment is provided by radiation therapy, or radiotherapy, comprising three-dimensional conformal radiation therapy and brachytherapy; and chemotherapy including photodynamic therapy.
In general, small-cell lung cancer (SCLC) is most commonly treated by chemotherapy in an attempt to slow or halt its spread beyond the lungs. Early stage non-small-cell lung cancer (NSCLC) is first treated by surgery and additional radiation therapy and chemotherapy to slow tumor growth and relieve symptoms, if required.
After surgery, if lymph nodes are positive in the resected lung tissues (stage II) or the mediastinum (peri-tracheal region, stage III), adjuvant chemotherapy may improve survival by up to 15%. However, the benefit of adjuvant chemotherapy for patients with stage I NSCLC is still controversial. Trials of preoperative chemotherapy in resectable NSCLC have been inconclusive (source: Clinical Evidence: concise, BMJ Publishing Group, London. 2006. ISBN 1-90554501206 ISSN 1465-9225). In the NCI Canada study JBR.10 (Pepe C. et al., J Clin Oncol. 2007; 25(12): 1553-61) patients with stage IB to IIB NSCLC were treated with vinorelbine and cisplatin chemotherapy and showed a significant survival benefit of 15% over 5 years. However subgroup analysis of patients in stage IB showed that chemotherapy did not result in any significant survival gain. Similarly, while the Italian ANITA study showed a survival benefit of 8% over 5 years with vinorelbine and cisplatin chemotherapy in stages IB to IIIA, subgroup analysis also showed no benefit in the IB stage (Douillard, J U. et al., Lancet Oncol 2006; 7(9): 719-27).
A Cancer and Leukemia Group B (CALGB) study (protocol 9633), related to a randomized trial of carboplatin and paclitaxel in stage IB NSCLC, reported no survival advantage at the June 2006 American Society of Clinical Oncology meeting. However, subgroup analysis suggested benefit for tumors greater than 4 centimeters. For patients with resected stage II-IIIA NSCLC, standard practice is to offer adjuvant third generation platinum-based chemotherapy (e.g. cisplatin and vinorelbine).
Chemotherapeutic drugs that are used in lung cancer treatment comprise platinum alkylators, podophyllin alkaloids, vinca alkaloids, anthracyclines, topoisomerase inhibitors, taxanes, antimetabolites, tyrosine kinase inhibitors, and folate antagonists in recent years, various molecular targeted therapies have been developed for the treatment of advanced lung cancer. Gefitinib (Iressa) targets the epidermal growth factor receptor (EGF-R) that is expressed in many cases of NSCLC. However it was not shown to increase survival, although females, Asians, non-smokers and those with the adenocarcinoma cell type appear to benefit from gefitinib.
Another drug called erlotinib (Tarceva), which also inhibits EGF-R, increases survival in lung cancer patients and has recently been approved by the FDA for second-line treatment of advanced non-small cell lung cancer.
The most common treatment for early stage SCLC is surgery if the cancer is confined to a single nodule. Surgery can be combined with either cisplatin or carboplatin together with etoposide. Chemotherapy in combination with radiation therapy improves the outcome of the therapy. Late stage SCLC is also treated by a combination of either cisplatin or carboplatin and etoposide. Other chemotherapeutic drugs, such as cyclophosphamide, doxorubicin, vincristine, ifosfamide, topotecan, paclitaxel, methotrexate, vinorelbine, gemcitabine, irinotecan and docetaxel in various combinations, are prescribed if SCLC becomes resistant to the aforementioned drugs. Metastasis to the brain, which often occurs in SCLC is treated by radiation therapy.
Treatment of NSCLC is primarily determined by the stage of the cancer. Stage 0 cancer, in which the cancer has not spread beyond the inner lining of the lung, is often curable by surgery alone. Treatment of stage 1 cancer, which has not spread to the lymph nodes, is often also limited to surgery, either lobectomy or segmentectomy. The 5-year survival rate of patients with stage 1 is 55-70%. For stage 2 cancer, in which the cancer has spread to some lymph nodes, nowadays surgery is almost always followed by chemotherapy. Stage 3 cancer, in which the cancer has spread to nearby tissue or to distant lymph nodes, and stage 4 cancer, in which the cancer has spread to distant organs, are treated by a combination of chemotherapy and radiation therapy. Surgery is sometimes performed to remove one or more localized cancer nodules.
Chemotherapy, including adjuvant therapy, usually causes side effects, such as nausea, vomiting, loss of appetite, loss of hair, mouth sores, and severe diarrhea. For all patients, the risk of cancer recurrence has to be weighted against the severe side effects caused by aggressive treatment. This especially accounts for stage 1 NSCLC patients, where the cancer has spread beyond the inner lining of the lung, but yet has not reached the lymph nodes. Patients with an increased risk for cancer recurrence will benefit from adjuvant therapy, while patients with a reduced risk will unnecessary suffer from the severe side effects caused by adjuvant therapy. Therefore, there is a need for a method of typing NSCLC patients to determine their risk of cancer recurrence.
Therefore, the invention provides a method for typing, a sample, preferably a RNA sample, of an individual suffering from non-small cell lung cancer or suspected of suffering there from, the method comprising providing a tissue sample from said individual comprising non-small cell lung cancer cells or suspected to comprise non-small cell lung cancer cells; preparing RNA from said tissue sample; determining RNA levels for a set of genes in said RNA; and typing said sample on the basis of the levels of RNA determined for said set of genes; wherein said set of genes comprises at least two of the genes listed in Table 3.
A level of RNA refers to the amount of RNA that is present in a sample, preferably relative to other RNA in said sample. Said level of RNA is a measure of the level of expression of a gene in cell of said tissue sample. It is preferred that said level of RNA refers to the amount of mRNA transcripts from a gene in a sample, preferably relative to other mRNA such as total mRNA.
The genes listed in Table 3 were identified and validated as being differentially expressed in non-small cell lung cancer samples. Non-small cell lung cancer samples were randomly divided into a training set and a validation set. In a first series of experiments, genes were identified of which the RNA level differs between a sample from an individual with a high risk for cancer recurrence versus a sample from an individual with a low risk of cancer recurrence, using the training set of cancer samples. The resulting genes were validated in a second series of experiments using the independent validation set of non small cell lung cancer samples. A gene set comprising at least two of the genes listed in Table 3 provides a prognostic signature for typing a sample of an individual suffering from non-small cell lung cancer as having a low risk or an enhanced risk of cancer recurrence. Prognostic information that can be obtained by a method of the invention comprises three possible endpoints, which are time from surgery to distant metastases, time of disease-free survival, and time of overall survival. Kaplan-Meier plots (Kaplan and Meier. J Am Stat Assoc 53: 457-481 (1958)) can be used to display time-to-event curves for any or all of these three endpoints.
Typing refers to assessing a risk of recurrence of said non-small cell lung cancer. Said typing is intended to provide prognostic information to aid in clinical evaluation of NSCLC patients. In this respect, no recurrence within a relevant time interval is defined as “low risk”, and recurrence within said relevant time interval is defined as “high risk”. A relevant time interval is at least 1 year, more preferred at least two years, more preferred at least three years, more preferred at least five years, or more preferred at least ten years.
A method of the invention is particularly suited to differentiate between a high or low risk of recurrence within three years.
Cancer recurrence refers to a recurrence of the cancer in the same place as the original cancer or elsewhere in the body. A local recurrence refers to a cancer that has returned in or very close to the same place as the original cancer, while a distant recurrence means the cancer has spread, or metastasized, to organs or tissues distant from the site of the original cancer.
Said tissue sample can be derived from all or part of a cancerous growth, or of a tumor suspected to be cancerous, depending on the size of the cancerous growth. A cancerous growth can be removed by surgical treatment including lobectomy, bilobectomy or pneumonectomy, with or without part of a bronchial tube. Said tissue sample can also be derived by biopsy, comprising aspiration biopsy, needle biopsy, incisional biopsy, and excisional biopsy. It is preferred that at least 10% of the cells in a tissue sample are NSCLC cells, more preferred at least 20%, and most preferred at least 30%. Said percentage of tumor cells can be determined by analysis of a stained section, for example hematoxylin and eosin-stained section, from the cancerous growth. Said analysis can be performed or confirmed by a pathologist.
Said individual suffering from NSCLC, or suspected of suffering from NSCLC, can be an individual suffering from stage 0 cancer, in which the cancer has macroscopically not spread beyond the inner lining of the lung, and which is often curable by surgery alone. Said individual can be suffering from stage 1 cancer, which has not spread to the lymph nodes; stage 2 cancer, in which the cancer has spread to some lymph nodes; stage cancer, in which the cancer has spread to nearby tissue or to distant lymph nodes; or stage 4 cancer, in which the cancer has spread to distant organs.
It is preferred that said individual suffers from early stage NSCLC, or suspected of suffering there from. Early stage NSCLC is stage 0 cancer, stage 1 cancer, or stage 2 cancer.
In a preferred embodiment, said individual is suffering from stage 1 NSCLC, or suspected of suffering there from.
A method of the invention is preferably used to determine a risk for said patient for recurrence of the cancer. This risk may further be combined with other prognostic factors such as age, sex, tumor diameter and smoking history. A determined risk can be used by a clinician to make a decision about which patients may benefit from additional chemotherapy, and which patients are not likely to benefit from additional chemotherapy.
RNA prepared from said tissue sample preferably represents a quantitative copy of genes expressed at the time of collection of a tissue sample from the cancer. This can be achieved by processing and storing said tissue sample under protective conditions that preserve the quality of the RNA. Examples of such preservative conditions are fixation using e.g. formaline, the use of RNase inhibitors such as RNAsin™ (Pharmingen) or RNAsecure™ (Ambion), and the use of preservative solutions such as RNAlater™ (Ambion) and RNARetain™ (Assuragen). It is further preferred that said preservative condition allows storage and transport of said tissue sample at room temperature. A preferred preservative condition is the use of RNARetain™ (Assuragen).
Said RNA sample can be isolated from said tissue sample by any technique known in the art, including but not limited to Trizol (Invitrogen; Carlsbad, Calif.), RNAqueous® Technology (Qiagen; Venlo, the Netherlands), Total RNA Isolation method (Agilent; Santa Clara, Calif.), and Maxwell™ 16 Total RNA Purification Kit (Promega; Madison, Wis.). A preferred RNA isolation procedure involves the use of RNAqueous® Technology (Qiagen; Venlo, the Netherlands).
For each of the genes listed in Table 3, a relative level of expression in a sample from an individual with a low risk of cancer recurrence was compared to the average level of expression in a reference sample comprising a mixture of non-small cell lung cancer samples. Said relative level of expression is either increased in a low risk NSCLC sample, as indicated with a positive number in the second column of Table 3, or said relative level of expression is decreased in a low risk NSCLC sample, as indicated with a negative number in the second column of Table 3.
In a preferred embodiment, one of said at least two genes is increased in a low risk NSCLC sample, compared to the average level of expression of said gene in a reference sample, while a second gene from said at least two genes is decreased in a low risk NSCLC sample compared to the average level of expression of said gene in a reference sample.
It is furthermore preferred that said set of genes comprises at least three of the genes hated in Table 3, more preferred four of the genes listed in Table 3, more preferred five of the genes listed in Table 3, more preferred six of the genes listed in Table 3, more preferred seven of the genes listed in Table 3, more preferred eight of the genes listed in Table 3, more preferred nine of the genes listed in Table 3, more preferred ten of the genes listed in Table 3, more preferred fifteen of the genes listed in Table 3, more preferred twenty of the genes listed in Table 3, more preferred thirty of the genes listed in Table 3, more preferred forty of the genes listed in Table 3, more preferred sixty of the genes listed in Table 3, more preferred seventy of the genes listed in Table 3, more preferred seventy-two of the genes listed in Table 3, more preferred eighty of the genes listed in Table 3, more preferred ninety of the genes listed in Table 3, more preferred hundred of the genes listed in Table 3, more preferred two-hundred of the genes listed in Table 3, more preferred all of the genes listed in Table 3.
It is furthermore preferred to select genes that are increased in a low risk NSCLC sample, compared to the average level of expression of said gene in a reference sample, as well as genes that are decreased in a low risk NSCLC sample compared to the average level of expression of said gene in a reference sample.
It is particularly preferred that said set of genes comprises at least four of the genes listed in Table 3 resulting in an average accuracy of 0.598837; more preferred at least nine of the genes listed in Table 3 resulting in an average accuracy of 0.6046512; more preferred at least forty-nine of the genes listed in Table 3 resulting in an average accuracy of 0.6337209; more preferred at least ninety of the genes listed in Table 3 resulting in an average accuracy of 0.6453488; more preferred all of the genes listed in Table 3 resulting in an average accuracy of 0.651163; as indicated in
The genes listed in Table 3 can be rank ordered. Ranking can be based on a correlation with overall survival time, or on a correlation with recurrence free survival time, or on a correlation with differential expression between tumor samples from low-risk and high-risk patients, or based on the selection percentages of the genes during the multiple samples approach (Michiel et al., Lancet 365: 488-92 (2005)), as is known to a skilled person. Ranking of the genes listed in Table 3 was performed according to their selection percentages during the multiple samples approach, in which the top-ranked genes represent the genes that were most often selected for development of the prognostic signature.
A preferred set of genes for use in a method of the invention comprises the first two rank-ordered genes listed in Table 3 resulting in negative predictive value of 0.7857143; more preferred the first eight rank-ordered genes listed in Table 3 resulting in negative predictive value of 0.8681319; more preferred the first thirty-six rank-ordered genes listed in Table 3 resulting in negative predictive value of 0.8829787; more preferred the first fifty-seven rank-ordered genes listed in Table 3 resulting in negative predictive value of 0.8977273; and most preferred the first seventy-two rank-ordered genes listed in Table 3 resulting in negative predictive value of 0.9166667, as indicated in
It is furthermore preferred that a set of genes for use in a method of the invention comprises at least two of the genes listed in Table 3, whereby one of said at least two genes is Ref Seq number XM—04626. In a more preferred embodiment, a set of genes according to the invention comprises Ref Seq number XM—04626 and Ref Seq number NM—052966; more preferred Ref Seq number XM—04626, Ref Seq number NM—052966, and Ref Seq number NM—002664; more preferred Ref Seq number XM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, and Ref Seq number NM—004310; more preferred Ref Seq number XM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, and Ref Seq number NM—004288; more preferred Ref Seq number NM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, Ref Seq number NM—004288 and Ref Seq number NM—003195; more preferred Ref Seq number NM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, Ref Seq number NM—004288, Ref Seq number NM—003195, and Ref Seq number NM—024560; more preferred Ref Seq number NM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, Ref Seq number NM—004288, Ref Seq number NM—003195, Ref Seq number NM—024560 and Ref Seq number NM—014358; more preferred Ref Seq number NM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, Ref Seq number NM—004288, Ref Seq number NM—003195, Ref Seq number NM—024560, Ref Seq number NM—014358, and Ref Seq number NM—201286; more preferred Ref Seq number NM—04626, Ref Seq number NM—052966, Ref Seq number NM—002664, Ref Seq number NM—004310, Ref Seq number NM—004288, Ref Seq number NM—003195, Ref Seq number NM—024560, Ref Seq number NM—014358, Ref Seq number NM—201286, and Ref Seq number NM—172006.
The genes listed in Table 3 can be identified by the gene name or by the unique identifier according to the NCBI Reference Sequences (Refseq), as provided in Table 3. Preferably, said genes can be identified by a part of the sequence of said gene which is provided in Table 3.
The RNA level of at least two of the genes listed in Table 3 can be determined by any method known in the art, including but not limited to Northern blotting, ribonuclease protection assay, multiplex technologies such as Locked Nucleic Acid-modified capture probes and multi-analyte profiling beads, quantitative polymerase chain reaction (qPCR), and microarray-mediated analyses. If required, an RNA sample can be reverse-transcribed by known methods, such as by random primed or by oligo (dT) primed reverse transcriptase reaction, into copy-DNA prior to determination of the expression level. qPCR comprises end point polymerase reaction and real-time polymerase reaction. Alternatives to PCR, such as strand-displacement amplification, branched DNA, loop-mediated isothermal amplification and nucleic-acid sequence based amplification are specifically included in this embodiment.
In a preferred method according to the invention, RNA levels are determined by means of an array or microarray.
(Micro)array-mediated analyses to determine RNA levels of at least two of the genes listed in Table 3 in a RNA sample comprises the use of a probe on a solid surface to determine the levels of a specific RNA that is present in a RNA from a tissue sample. Said probe can be a desoxyribonucleic acid (DNA) molecule such as a genomic DNA or fragment thereof, a ribonucleic acid molecule, a cDNA molecule or fragment thereof, a PCR product, a synthetic oligonucleotide, or any combination thereof. Said probe can be a derivative or variant of a nucleic acid molecule, such as, for example, a peptide nucleic acid molecule.
Said probe is specific for a gene listed in Table 3. A probe can be specific when it comprises a continuous stretch of nucleotides that are completely complementary to a nucleotide sequence of a RNA product of said gene, or a cDNA product thereof. A probe can also be specific when it comprises a continuous stretch of nucleotides that are partially complementary to a nucleotide sequence of a RNA product of said gene, or a cDNA product thereof. Partially means that a maximum of 5% from the nucleotides in a continuous stretch of at least 20 nucleotides differs from the corresponding nucleotide sequence of a RNA product of said gene. The term complementary is known in the art and refers to a sequence that is related by base-pairing rules to the sequence that is to be detected. It is preferred that the sequence of the probe is carefully designed to minimize nonspecific hybridization to said probe. It is preferred that the probe is or mimics a single stranded nucleic acid molecule. The length of said complementary continuous stretch of nucleotides can vary between 15 bases and several kilo bases, and is preferably between 20 bases and 1 kilobase, more preferred between 40 and 100 bases, and most preferred 60 nucleotides.
To determine the RNA level of at least two of the genes listed in Table 3, the RNA sample is preferably labeled, either directly or indirectly, and contacted with probes on the array under conditions that favor duplex formation between a probe and a complementary molecule in the labeled RNA sample. The amount of label that remains associated with a probe after washing of the microarray can be determined and is used as a measure for the level of RNA of a nucleic acid molecule that is complementary to said probe.
Systemic bias can be introduced during the handling of the sample in a microarray experiment. To reduce systemic bias, the determined RNA levels are preferably corrected for background non-specific hybridization and normalized using, for example, Feature Extraction software (Agilent Technologies). Other methods that are or will be known to a person of ordinary skill in the art, such as a dye swap experiment (Martin-Magniette et al., Bioinformatics 21:1995-2000 (2005)) which can be performed to normalize differences introduced by dye bias, can, also be applied.
In a preferred method according to the invention, the determination of the RNA levels comprises normalizing the determined levels of RNA of said set of genes in said sample.
Normalization corrects for variation due to inter-array differences in overall performance, which can be due to for example inconsistencies in array fabrication, staining and scanning, and variation between labeled RNA samples, which can be due for example to variations in purity. Conventional methods for normalization of array data include global analysis, which is based on the assumption that the majority of genetic markers on an array are not differentially expressed between samples [Yang et al., Nucl Acids Res 30: 15 (2002)]. Alternatively, the array may comprise specific probes that are used for normalization. These probes preferably detect RNA products from housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase and 18S rRNA levels, of which the RNA level is thought to be constant in a given cell and independent from the developmental stage or prognosis of said cell. Said specific probes preferably are specific for genes of which the RNA level varies over a wide range of levels.
In a preferred embodiment, a method of the invention further comprises comparing an RNA level at least two of the genes listed in Table 3 to an RNA level of said genes in a reference sample.
The reference sample can be an RNA sample isolated from a lung tissue from a healthy individual, or from so called normal adjacent tissue from an individual suffering from NSCLC, or an RNA sample from a relevant cell line or mixture of cell lines. Said reference sample can also be an RNA sample from a cancerous growth of an individual suffering from NSCLC. Said individual suffering from NSCLC can have an increased risk of cancer recurrence, or a low risk of cancer recurrence.
It is preferred that said reference sample is an RNA sample from an individual suffering from non-small cell lung cancer and having a low risk of cancer recurrence. In a more preferred embodiment, said reference sample is a pooled RNA sample from multiple tissue samples comprising NSCLC cells from individuals suffering from non-small cell lung cancer and having a low risk of cancer recurrence. It is preferred that said multiple tissue sample comprise more than 10 tissue samples, more preferred more than 20 tissue samples, more preferred more than 30 tissue samples, more preferred more than 40 tissue samples, most preferred more than 50 tissue samples.
Comparison of a sample with a reference sample can be performed in various ways. Preferably a coefficient is determined that is a measure of the similarity of dissimilarity of a sample with said reference sample. A number of different coefficients can be used for determining a correlation between the RNA expression level in an RNA sample from an individual and a reference sample. Preferred methods are parametric methods which assume a normal distribution of the data. One of these methods is the Pearson product-moment correlation coefficient, which is obtained by dividing the covariance of the two variables by the product of their standard deviations. Preferred methods comprise cosine-angle, un-centered correlation and, more preferred, cosine correlation (Fan et al., Conf Proc IEEE Eng Med Biol Soc. 5:4810-3 (2005)).
Preferably, said correlation with a reference sample is used to produce an overall similarity score for the set of genes that are used. A similarity score is a measure of the average correlation of RNA levels of a set of genes in an RNA sample from an individual and a reference sample. Said similarity score is a numerical value between +1, indicative of a high correlation between the RNA expression level of the set of genes in the RNA sample of the individual and the reference sample, and −1, which is indicative of an inverse correlation and therefore indicative of having an increased risk of cancer recurrence (van 't Veer et al., Nature 415: 484-5 (2002)).
In particularly preferred embodiment, an arbitrary threshold is determined for said similarity score. RNA samples that score below said threshold are indicative of an increased risk of cancer recurrence, while samples that score above said threshold are indicative of a low risk of cancer recurrence.
A similarity score and or a resultant of said score, which is a measurement of increased risk or low risk of cancer recurrence, is preferably displayed or outputted to a user interface device, a computer readable storage medium, or a local or remote computer system.
In another aspect, the invention provides a set of probes for typing a sample of an individual suffering from NSCLC, or suspected of suffering therefrom, wherein said set of probes comprises probes that are specific for at least two of the genes listed in Table 3.
The RNA level of a set of genes comprising at least two of the genes listed in Table 3 was found to be discriminative between an RNA sample from an individual suffering from NSCLC and having an increased risk for recurrence of said cancer, and an RNA sample from an individual suffering from NSCLC and having an reduced risk for recurrence of said cancer.
It is preferred that said set probes comprises probes that are specific for at least three of the genes listed in Table 3, more preferred four of the genes listed in Table 3, more preferred five of the genes listed in Table 3, more preferred six of the genes listed in Table 3, more preferred seven of the genes listed in Table 3, more preferred eight of the genes listed in Table 3, more preferred nine of the genes listed in Table 3, more preferred ten of the genes listed in Table 3, more preferred fifteen of the genes listed in Table 3, more preferred twenty of the genes listed in Table 3, more preferred thirty of the genes listed in Table 3, more preferred forty of the genes listed in Table 3, more preferred sixty of the genes listed in Table 3, more preferred seventy of the genes listed in Table 3, more preferred seventy-two of the genes listed in Table 3, more preferred eighty of the genes listed in Table 3, more preferred ninety of the genes listed in Table 3, more preferred hundred of the genes listed in Table 3, more preferred two-hundred of the genes listed in Table 3, more preferred all of the genes listed in Table 3.
Preferably said set of probes comprises probes specific for not more than 227 different genes, more preferred not more than 150 different genes, more preferred not more than 72 different genes of the genes listed in Table 3.
In yet another aspect, the invention provides the use of a set of probes that are specific for a set of genes of the invention for determining a risk for an individual suffering of NSCLC or suspected of suffering from said cancer, for recurrence of said cancer.
According to this aspect, the invention provides the use of set of probes that are specific for a set of genes of the invention for discriminating between NSCLC cells with a low versus a high metastasizing potential by determining a nucleic acid level of expression of said set of marker genes in an RNA sample from a patient suffering from NSCLC or suspected of suffering from said cancer.
The invention furthermore provides an array comprising between 2 and 12.000 probes of which two or more probes are specific for at least two of the genes listed in Table 3. The invention furthermore provides the use of an array according to the invention for typing of NSCLC cells.
The invention also provides a set of primers for typing a sample of an individual suffering from non-small cell lung cancer or suspected of suffering there from, whereby said set of primers comprises primers specific for at least two of the genes listed in Table 3.
Said set of primer can be used for determining an RNA level for said at least two of the genes listed in Table 3 in a sample. Known methods for determining an RNA level comprise amplification methods, including but not limited to polymerase chain reaction such as multiplex PCR and multiplex ligation-dependent probe amplification, and nucleic acid sequence-based amplification.
Preferably said set of primers comprises primers specific for less than 227 different genes, more preferred not more than 150 different genes, more preferred not more than 72 different genes of the genes listed in Table 3.
According to this aspect, the invention further provides the use of a set of primers according to the invention for determining a risk for an individual suffering of NSCLC for recurrence of said cancer. The invention also provides the use of a set of primers according to the invention for discriminating between NSCLC cells with a low versus a high metastasizing potential.
In a further aspect, the invention provides a method of classifying a sample from an individual suffering from NSCLC, or suspected of suffering from NSCLC, comprising classifying a sample as derived from an individual having a poor prognosis or a good prognosis by a method comprising providing a sample from said individual; determining a level of RNA for a set of genes comprising at least two of the genes listed in Table 3 in said sample; determining a similarity value for the level of RNA in said sample and a level of RNA for said set of genes in a patient having no recurrent disease within three years of initial diagnosis; and classifying said individual as having a poor prognosis if said similarity value is below a first similarity threshold value, and classifying said individual as having a good prognosis if said similarity value exceeds said first similarity threshold value.
Said reference sample is preferably a sample from normal lung tissue, from normal adjacent tissue, from a cell line or mixture of cell lines, or a relevant sample from an individual suffering from NSCLC. Preferably, a reference sample is from an individual suffering from non-small cell lung cancer and having a low risk of cancer recurrence. In a more preferred embodiment, said reference sample is a pooled RNA sample from multiple tissue samples comprising NSCLC cells from individuals suffering from non-small cell lung cancer and having a low risk of cancer recurrence.
A reference sample can also comprise a sample from an individual suffering from non-small cell lung cancer and having an increased risk of cancer recurrence. In that instance, the invention similarly provides a method of classifying an individual suffering from NSCLC, or suspected of suffering from NSCLC, comprising classifying a sample as derived from an individual having a poor prognosis or a good prognosis by a method comprising providing a sample from said individual; determining a level of RNA for a set of genes comprising at least two of the genes listed in Table 3 in said sample; determining a similarity value for the level of RNA in said sample and a level of RNA for said set of genes in a patient having recurrent disease within three years of initial diagnosis; and classifying said individual as having a good prognosis if said similarity value is below a first similarity threshold value, and classifying said individual as having a poor prognosis if said similarity value exceeds said first similarity threshold value.
Non small cell lung cancer samples were analyzed on Agilent 44K array against a lung reference pool that consisted of a pool of RNA from 65 NSCLC samples. A total of 103 samples were used for training the predictive signature and 69 as an independent validation set. The samples originated from 5 different European institutes and included mainly squamous cell carcinomas and adenocarcinomas. An overview of the sample and patient characteristics is given in Table 1. All samples were taken with informed consent of the patients according to the ethical standards of the Helsinki Declaration. RNA isolation and cRNA labeling followed standard protocols (Glas et al., BMC Genomics 2006; 7: 278). Hybridization was performed on Agilent platform (Agilent 44K arrays) according to standard procedures described by the manufacturer and as described elsewhere (Glas et al., BMC Genomics 2006; 7: 278). R and Bioconductor packages, available from the Bioconductor project (www.bioconductor.org), were used for statistical analyses of the data.
A leave-one-out cross validation procedure for development of a nearest-mean classifier did not result in a signature that could be validated using this type of cross validation procedure (
A 10-fold cross validation procedure was used for a more robust and less biased identification of predictive genes (
To develop a classifier with optimal performance for prediction of overall survival (OS) as well as relapse-free survival (RFS), the gene selection scores generated by the multiple samples procedure for OS and RFS were ranked and genes with a high ranking in both survival analyses were selected. Starting with a minimal list of the 40 highest ranked genes, the set of predictive genes was gradually expanded to determine the optimal gene set size with the highest predictive accuracy (both for OS and RFS) on all training samples (
The predictive signature was validated on an independent set of 69 validation samples (Table 1). The gene expression profiles of the validation samples indicated that the predictive signature is also present in independent samples (
The sensitivity, specificity, negative predictive value (NPV), positive predictive value and overall accuracy of the classifier (Table 2) confirm the finding that the classifier is able to discriminate between patients with a low and high risk for disease progression, especially towards prediction of low-risk patients (NPV of 9.3 percent on the validation set). The median overall survival time of low-risk and high-risk patients is 47 and 31 months, respectively (P<1e-4, Wilcoxon rank-sum test) and the median relapse-free survival time for both patients groups is 47 versus 24 months, respectively (P<1e-5) (Table 4).
To determine the minimal number of signature genes that are needed for an accurate prognostic signature, the set of 237 genes was ranked according to the prognostic power of the individual genes and the set of 237 genes was sequentially reduced till a gene set comprising only the two top ranked genes. For each different gene set size (i.e. comprising from 2 genes up to 237 genes) the negative predictive value (NPV), positive predictive value (PPV) and total accuracy were determined for prognosis off overall survival for at least 3 years.
We further analyzed the performance of a random subset of 2 or more genes selected from the set of 237 genes. Random subsets were selected with different sizes ranging from 2 genes up to all 237 genes. In total, hundred random, computer generated subsets were selected if possible for each different size and for each different subset the NPV, PPV and total accuracy was calculated. Subsequently, the mean performance and the 95 percent confidence interval were calculated for each different subset size. The data shown in
To test whether the classifier predicted survival independently of the other two prognostic factors, tumor type and tumor grade (
aLog-rank test
bWilcoxon rank sum test
C. elegans)
| Number | Date | Country | Kind |
|---|---|---|---|
| 07109466.8 | Jun 2007 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/NL08/50342 | 6/2/2008 | WO | 00 | 1/14/2010 |
